Drugs for percutaneous coronary interventions.

Published

Journal Article

Many combinations of anticoagulants and antiplatelet drugs have been used to treat patients undergoing a percutaneous coronary intervention (PCI). Among anticoagulants, enoxaparin has some theoretical advantages over unfractionated heparin, but in clinical trials no advantage in outcome has been demonstrated in PCI. Bivalirudin, a direct thrombin inhibitor, has been associated with a lower risk of bleeding than unfractionated heparin. Among antiplatelet drugs, use of clopidogrel plus aspirin has led to a reduction in cardiovascular events; all patients undergoing PCI should receive both. Addition of a GP IIb/IIIa inhibitor may lower mortality rates further, particularly in high-risk patients such as diabetics.

Full Text

Duke Authors

Published Date

  • December 6, 2004

Published In

Volume / Issue

  • 47 / 1197-1198

Start / End Page

  • 100 - 102

PubMed ID

  • 15583527

Pubmed Central ID

  • 15583527

International Standard Serial Number (ISSN)

  • 0025-732X

Language

  • eng

Conference Location

  • United States